Lytix Biopharma ASA · OSL:LYTIX
Lytix Biopharma ASA — Q1 2023 Earnings Presentation
22 slides from Lytix Biopharma ASA's earnings presentation, May 11, 2023
Slide 1: Lytix Biopharma AS First quarter 2023 presentation
Lytix Biopharma AS New class of immunotherapy First quarter 2023 presentation May 11, 2023
Slide 2: Disclaimer
Disclaimer This presentation (the "Presentation") has been prepared by Lytix Biopharma AS ("Company") exclusively for information purposes. The Presentation is being made only to, and is only directed at, persons to whom such presentation may lawfully be communicated (’relevant persons’). Any person
Slide 3: Presenting team
Presenting team Øystein Rekdal / CEO and co-founder • Dr. Rekdal’s post-doctoral research forms the basis of Lytix Biopharma’s oncolytic molecule platform. • Over the last years Rekdal has been instrumental in the development of intra-tumoral therapy of LTX-315 from preclinical to clinical ‘proof of
Slide 4: Scientifically and commercially validated
Scientifically and commercially validated Unique non-viral oncolytic platform with broad pipeline opportunities Innovative pipeline that overcomes major • Lead candidate; one completed challenges in cancer therapy and two ongoing Phase II studies • Tumor heterogeneity • Second generation molecule: •
Slide 5: Highlights for the first quarter
Highlights for the first quarter ATLAS-IT-05 Countries with active sites ‒ All six sites in Europe are now open and actively recruiting patients ‒ One new site in the US opened during the quarter – UPMC Hillman Cancer Center Verrica Pharmaceuticals has completed treatment in part 1 of three parts of
Slide 6: Post period events
Post period events Following the positive safety assessment and promising signs of activity from Part 1 of the study, Verrica advanced into the second part of their ongoing Phase 2 study in basal cell carcinoma in April 2023 At Lytix’ Annual General Meeting, Marie Roskrow was elected as new Chairper
Slide 7: Clinical/Operational update
Clinical/Operational update
Slide 8: ATLAS-IT-05 - heading for complete recruitment
ATLAS-IT-05 - heading for complete recruitment The clinical trial application approved under EU`s clinical trial regulation ‒ Six sites are active in Norway, Spain and France ‒ Three sites are active in the US and a fourth site is close to opening ‒ The sites are recognized for intratumoral immunoth
Slide 9: Verrica Pharmaceuticals - Phase II study in good progress
Verrica Pharmaceuticals - Phase II study in good progress Verrica has completed treatment in part 1 of three parts of their ongoing Phase II study evaluating LTX-315 in basal cell carcinoma (BCC) Part 2 of the Phase II trial started in April 2023 and will further explore dosing regimens allowing ide
Slide 10: LTX-401 - Lytix' next generation oncolytic molecule
LTX-401 - Lytix` next generation oncolytic molecule Activities progressing as planned to submit a Clinical Trial Application to start a Phase I study Liver cancers represent large cancer segments with high unmet medical need and modest effect with checkpoint inhibitors LTX-401 may solve the high unm
Slide 11: Pipeline
Pipeline Product Description Indication Discovery Preclinical Phase I Phase II Phase III candidate ATLAS-IT-05 Melanoma patients Pembrolizumab progressed on (Keytruda®) checkpoint inhibitors Phase II by Verrica LTX-315 Pharmaceuticals Basal cell carcinoma (monotherapy) ATLAS-IT-04 Advanced soft tiss
Slide 12: Key figures
Key figures
Slide 13: Key figures – profit and loss
Key figures – profit and loss Unaudited Unaudited Amounts in NOK thousands Q1 2023 Q1 2022 FY 2022 Total operating income 375 1,509 17,273 Total operating expenses (24,846) (16,182) (82,968) Loss from operations (24,471) (14,673) (65,695) Loss for the period (19,673) (15,231) (56,006) Total operatin
Slide 14: Key figures - high level of activity
Key figures - high level of activity 30 000 20 000 Total operating expense Direct R&D expenses 15 000 20 000 10 000 10 000 5 000 0 0 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 2023 2022 2023 2022 30 000 Operating expenses 22/23 Cash and short term financial investments 200 000 20 000 150 000 10 000 100 000 0 50 000 22
Slide 15: Key figures – balance sheet
Key figures – balance sheet Unaudited Unaudited Amounts in NOK thousands 31.03.2023 31.03.2022 31.12.2022 Assets Property, plant and equipment 126 35 124 Trade and other receivables 7,073 7,242 6,735 Short-term financial investments 51,314 0 50,606 Cash and cash equivalents 75,057 180,666 94,552 Tot
Slide 16: Outlook
Outlook
Slide 17: Key objectives moving forward
Key objectives moving forward Clinical development ‒ Expand the clinical impact field for LTX-315 LTX-315 MONOTHERAPY and drive enrollment in the ATLAS-IT-05 Local treatment Abscopal effect Phase II trial towards completion ‒ Continue to support Verrica Pharmaceuticals’ Phase II trial with LTX-315
Slide 18: Q&A
Q&A IR enquiries: ole.peter.nordby@lytixbiopharma.com
Slide 19: Interim Financial Statements
Interim Financial Statements
Slide 20: Condensed Interim statement of profit and loss
Condensed Interim statement of profit and loss Unaudited Unaudited Amounts in NOK thousands Q1 2023 Q1 2022 FY 2022 Revenue - - 1,409 Other operating income 375 1,509 15,864 Total operating income 375 1,509 17,273 Payroll and related expenses (5,289) (3,700) (21,133) Depreciation and amortization ex
Slide 21: Condensed Interim statement of financial position
Condensed Interim statement of financial position Unaudited Unaudited Amounts in NOK thousands 31.03.2023 31.03.2022 31.12.2022 Assets Non-current assets Property, plant and equipment 126 35 124 Total non-current assets 126 35 124 Current assets Trade and other receivables 7,073 7,242 6,735 Short-te
Slide 22: Condensed Interim statement of cash flows
Condensed Interim statement of cash flows Unaudited Unaudited Amounts in NOK thousands Q1 2023 Q1 2022 FY 2022 Cash flows from operating activities Loss for the period (19,673) (15,231) 56,006) Adjustments for: Depreciation of property, plant and equipment 14 - 30 Share-based payment expense 1,019 2